Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Oct 3, 2021 in Lung cancer | 0 comments

In a nutshell

This study evaluated the effectiveness and safety of combining cranial radiotherapy (CRT; radiotherapy tot the head) with and without anlotinib (AL3818) for the treatment of patients with non-small cell lung cancer (NSCLC) and brain metastases (BM). The data showed that anlotinib plus CRT significantly improved survival without brain tumors worsening for these patients.

Some background

NSCLC is the most common form of lung cancer. NSCLC is responsible for around 85% of all lung cancer diagnoses. Treatment for NSCLC includes chemotherapy, radiotherapy, and surgical removal of tumors. In 20-40% of cases, NSCLC spreads from the lung to the brain. The most common treatment for BM is CRT.

Anlotinib is a tyrosine kinase inhibitor (TKI). TKIs block enzymes that are responsible for many cellular functions in the body. Anlotinib works by stopping tumors from forming new blood vessels and spreading. Anlotinib has been shown to improve survival outcomes in patients with NSCLC and BM. However, there are few studies evaluating the effectiveness and safety of CRT combined with anlotinib for the treatment of patients with NSCLC and BM.

Methods & findings

This study involved 73 patients with NSCLC and BM. The patients were divided into 2 groups. Group 1 included 28 patients who received anlotinib plus CRT. Group 2 included 45 patients who received CRT alone. The average follow-up time was 9.82 months.

Overall, 89.3% of patients in group 1 responded to treatment compared to 80% of patients in group 2. The average survival without cancer progression in the brain was significantly higher in group 1 (11 months) compared to group 2 (3 months). Anlotinib plus CRT significantly decreased the risk of cancer progression by 48% compared to CRT alone.

The average overall survival was slightly longer for group 1 (8.5 months) compared to group 2 (6 months).

The bottom line

This study concluded that anlotinib plus CRT significantly improved survival without cancer progression in the brain for the treatment of patients with NSCLC and BM.

The fine print

This study looked back in time at medical records. The sample size was very small. Larger studies with longer follow-up times are needed to fully validate the conclusions of this study.

Published By :

Cancer management and research

Date :

Aug 12, 2021

Original Title :

Anlotinib Combined with Cranial Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Retrospectively, Control Study.

click here to get personalized updates